As of 2026-04-30, the Intrinsic Value of Aurinia Pharmaceuticals Inc (AUPH) is 21.14 USD. This AUPH valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 15.28 USD, the upside of Aurinia Pharmaceuticals Inc is 38.40%.
The range of the Intrinsic Value is 15.50 - 34.51 USD
Based on its market price of 15.28 USD and our intrinsic valuation, Aurinia Pharmaceuticals Inc (AUPH) is undervalued by 38.40%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 15.50 - 34.51 | 21.14 | 38.4% |
| DCF (Growth 10y) | 20.66 - 44.18 | 27.68 | 81.2% |
| DCF (EBITDA 5y) | 17.71 - 19.21 | 18.44 | 20.7% |
| DCF (EBITDA 10y) | 22.02 - 25.41 | 23.64 | 54.7% |
| Fair Value | 54.00 - 54.00 | 54.00 | 253.39% |
| P/E | 15.30 - 15.34 | 15.32 | 0.2% |
| EV/EBITDA | 14.91 - 28.08 | 20.45 | 33.9% |
| EPV | 2.28 - 2.83 | 2.56 | -83.3% |
| DDM - Stable | 22.40 - 68.19 | 45.30 | 196.4% |
| DDM - Multi | 14.09 - 33.58 | 19.88 | 30.1% |
| Market Cap (mil) | 2,031.78 |
| Beta | 0.27 |
| Outstanding shares (mil) | 132.97 |
| Enterprise Value (mil) | 2,020.47 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.30% |
| Cost of Debt | 5.00% |
| WACC | 8.19% |